【学习经历】 2005/09-2012/06，山东大学，药学院，获博士学位 1992/09-1995/07，山东医科大学，药学院，获硕士学位 1988/09-1992/07，聊城师范学院，化学系，获学士学位 【工作经历】 2005/09-至今山东大学，药学院，副教授 2009/07-2010/07，美国弗吉尼亚联邦大学，药物化学系，访问学者 1998/01-2005/09，山东大学，药学院，讲师 1995/07-1997/12，山东医科大学，药学院，助教

基于靶标的抗肿瘤药物研究 主要针对细胞信号转导通路、肿瘤相关表观遗传学等进行小分子靶向抗肿瘤药物的设计、合成与活性研究。 抗阿尔茨海默症（AD）药物研究 基于表观遗传学调节与阿尔茨海默症（AD）发病机制进行合理药物设计、合成与评价研究。

1.Ying-Jie Cui,Chao Liu,Chen-Chen Ma, Ya-Ting Ji, Yi-Li Yao, Long-Qian Tang, Cheng-Mei Zhang,Jing-De Wu*and Zhao-Peng Liu*. SAR Investigation and Discovery of Water-Soluble 1‑Methyl-1,4-dihydroindeno[1,2‑c]pyrazoles as Potent Tubulin Polymerization Inhibitors.J. Med. Chem. 2020, 63, 14840-14866. 2.Feng He,Yingying Ran,Xiaoyang Li,Defeng Wang, Qiuqiong Zhang, Jiahui Lv,Chenggong Yu, Ying Qu, Xiangna Zhang, Ana Xu, Chao Wei, C. James Chou,Jingde Wu*. Design, synthesis and biological evaluation of dual-function inhibitors targeting NMDAR and HDAC for Alzheimer’s disease.Bioorg. Chem. 2020,103,104109. 3.Ana Xu, Feng He, Xiangna Zhang, Xiaoyang Li, Yingying Ran, Chao Wei, C. James Chou, Rui Zhang,Jingde Wu*. Tacrine-hydroxamate derivatives as multitarget-directed ligands for the treatment of Alzheimer’s disease: Design, synthesis, and biological evaluation.Bioorg. Chem. 2020,98,103721. 4.Jing-De Wu, Ying-Jie Cui, Yi-Gang Zhou, Long-Qian Tang, Cheng-Mei Zhang, Zhao-Peng Liu*. Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.INVEST NEW DRUG.2020,38:29-38. 5.Ying Qu, Feifei Sun, Feng He, Chenggong Yu, Jiahui Lv, Qiuqiong Zhang, Dong Liang, Chen Yu, Jun Wang, Xiangna Zhang, Ana Xu,Jingde Wu*. Glycyrrhetinic acid-modified graphene oxide mediated siRNA delivery for enhanced liver-cancer targeting therapy.Eur J Pharm Sci. 2019,139,105036. 6.Qiuqiong Zhang, Jiahui Lv, Feng He, Chenggong Yu, Ying Qu, Xiangna Zhang, Ana Xu,Jingde Wu*. Design, synthesis and activity evaluation of indole-based double – Branched HDAC1 inhibitors.Bioorg Med Chem. 2019,27,1595-1604. 7.Zhang, Xiangna, He, Feng, Zhang, Qiuqiong, Lü, Jiahui, Xu, A'na, Yu, Chenggong, Qu, Ying,Wu, Jingde*. Design, Synthesis and Evaluation of Anti-tumor Activities of Chidamide Derivatives.Chin. J. Org. Chem. 2019, 39, 1983-1989. 8. Chenggong Yu, Feng He, Ying Qu, Qiuqiong Zhang, Jiahui Lv, Xiangna Zhang, Ana Xu, Pannan Miao,Jingde Wu*. Structure optimization and preliminary bioactivity evaluation of N- hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.Bioorg Med Chem. 2018,26,1859-1868 9. Shuai Tan, Feng He, Tingting Kong,Jingde Wu*, Zhaopeng Liu*. Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.Bioorg. Med. Chem.2017,25, 4123-4132. 10. Xue Wang, Xiaoyang Li, Jingyao Li, Jinning Hou, Ying Qu,Chenggong Yu, Feng He, Wenfang Xu,Jingde Wu*. Design, synthesis, and preliminary bioactivity evaluation of N1-hydroxyterephthalamide derivatives with indole cap as novel histone deacetylase inhibitors.Chem Biol Drug Des. 2017, 89: 38-46. 11. Yuqi Jiang, Xiaoyang Li, Xue Wang, Zhonglan Wang, Jian Zhang,Jingde Wu*, Wenfang Xu. Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents.Chem Biol Drug Des. 2016, 88: 542-555.